COMMUNIQUÉS West-GlobeNewswire

Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
01/05/2024
Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment to be easily accessible in case of an emergency GAITHERSBURG, [...]
WAKE RADIOLOGY TEAM RALLIES TO SUPPORT TRIANGLE RACE FOR THE CURE
01/05/2024
RESEARCH TRIANGLE PARK, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- Wake Radiology UNC REX Healthcare, the oldest and largest outpatient imaging provider in the Triangle, announced today it is once again sponsoring the Susan [...]
Seasoned Physician Executive Joins Nymbl Science
01/05/2024
Digital health leader welcomes Dr. Bob Mirsky as Chief Medical Officer DENVER, May 01, 2024 (GLOBE NEWSWIRE) -- Nymbl Science , a digital health provider and leader in scalable fall prevention and bladder training for [...]
Simms/Mann Family Foundation Recognizes Extraordinary Nurses in Second Year of “Off the Chart: Rewarding Nursing Greatness” Campaign
01/05/2024
Forty nurses from Los Angeles-area health systems each receive a $10,000 gift of gratitude for their leadership, ingenuity and expertise in caring for their fellow humans and future generations LOS ANGELES, May 01, 2024 [...]
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
01/05/2024
End-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ. Monday, May 6, 2024, Will be the Last and Final Day to Cash-Exercise SAVAW Warrants. ‘Notice of Guaranteed Delivery’ [...]
H1 Appoints Seasoned Marketing & Technology Executive Karen Walker to Its Board of Directors
01/05/2024
The former Intel and Cisco CMO and current Eli Lilly & Co. and Sprout Social board member will help H1 scale into the next phase of growth NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- H1 , the digital health innovator [...]
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
01/05/2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of [...]
Aeroflow Health Announces Expanded Access to Lactation Consultants, Supporting New Mothers Across all 50 States
01/05/2024
The durable medical equipment provider is increasing the size of its network of lactation consultants and its insurance providers to continue improving maternal health outcomes ASHEVILLE, N.C., May 01, 2024 (GLOBE [...]
The Pediatric Brain Tumor Foundation Welcomes Dr. Sanjay Gupta to its Board of Directors
01/05/2024
Dr. Gupta brings his experience as an accomplished neurosurgeon and longtime CNN chief medical correspondent to the PBTF in service of the pediatric brain cancer community ATLANTA, May 01, 2024 (GLOBE NEWSWIRE) -- The [...]
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
01/05/2024
Oral Presentation and Four Posters to Highlight Alkeus’ Progress in Advancing Research to Address Unmet Needs for People Affected by Serious Degenerative Eye Diseases CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- [...]
WeightWatchers for Business and Personify Health Partner to Help Employers Address Weight Health Care
01/05/2024
Personify Health clients will now have integrated access to WeightWatchers for Business’s full-spectrum weight health platform NEW YORK and PROVIDENCE, R.I., May 01, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW [...]
SFWJ/MedCana Reacts to US DEA's Rescheduling of Marijuana
01/05/2024
AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- via IBN -- SFWJ, doing business as MedCana, a holding company focused in the cannabis and agricultural technology sectors, joins the cannabis industry in acknowledging a [...]
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
01/05/2024
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 [...]
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
01/05/2024
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering AUSTIN, Texas, May 01, 2024 ( [...]
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
01/05/2024
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response Rate in Patients [...]
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
01/05/2024
The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance MALVERN, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical [...]
Novo Nordisk A/S - share repurchase programme
01/05/2024
Bagsværd, Denmark, 1 May 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
01/05/2024
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, [...]
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
01/05/2024
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker [...]

Pages